Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / OMER - Omeros: Still Worth A Look Despite Narsoplimab Woes

OMER - Omeros: Still Worth A Look Despite Narsoplimab Woes

Omeros Corporation

2024-02-14 08:30:24 ET

Summary

  • Omeros has suffered from underperformance of its Narsoplimab lead therapy.
  • OMIDRIA, Omeros' sole approved therapy, has provided significant cash infusions as Omeros has sold it off piecemeal.
  • Well situated for liquidity over the next two years, Omeros will need to raise significant funds thereafter.

...

For further details see:

Omeros: Still Worth A Look Despite Narsoplimab Woes
Stock Information
Company Name: Omeros Corporation
Stock Symbol: OMER
Market: NASDAQ
Website: omeros.com
Menu
OMER OMER Quote OMER Short OMER News OMER Articles OMER Message Board
Get OMER Alerts

News, Short Squeeze, Breakout and More Instantly...